ClinicalTrials.gg
Active, not recruitingNCT06351020Updated Feb 6, 2026

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

A Phase 3 interventional study of LM-302 and Apatinib in Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, sponsored by LaNova Medicines Zhejiang Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by LaNova Medicines Zhejiang Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
387
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study will assess the efficacy and safety of LM-302 Versus Treatment of Physician's Choice (TPC) in Subjects With locally advanced or metastatic, Claudin (CLDN) 18.2-positive, Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy

02

Conditions studied

  • Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
03

In context

Lead sponsor

LaNova Medicines Zhejiang Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years old, male and female
  • Has histopathologically confirmed unresectable locally advanced or adenocarcinoma of the gastric/gastroesophageal junction (G/GEJ AC).
  • Has received and progressed on at least 2 . A prior (neo) systemic therapy that ended within 6 months prior to disease relapse is defined as the first line therapy.
  • Centrally confirmed CLDN18.2-positive
  • negative
  • At least one according to the solid tumor response Evaluation Criteria ( 1.1)
  • : 0-1
  • Expected survival ≥12 weeks;
  • Good blood reserve and liver, kidney and coagulation function
  • Willing to provide for study participation.

Exclusion criteria

Exclusion Criteria:

  • Within the first 5 years of randomization, there is a history of malignant tumors other than GC/GEJ adenocarcinoma, except for skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, and skin squamous cell carcinoma that have been cured and cured after treatment
  • Individuals with a history of previous immunodeficiency, including those with other acquired or congenital immunodeficiency diseases, or those with a history of organ transplantation, bone marrow transplantation, or autologous hematopoietic stem cell transplantation
  • Urine protein qualitative result ≥ 3+, or urine protein qualitative result is 2+and 24-hour urine protein quantification>1g
  • Individuals with a history of severe cardiovascular and cerebrovascular diseases
  • Individuals who are unable to control or have serious illnesses, including but not limited to active infections requiring systemic antibiotic treatment within 2 weeks prior to initial medication, interstitial pneumonia/lung disease requiring intervention during screening, and tumor related pain requiring local treatment during screening
  • Current peripheral sensory or motor neuropathy ≥ grade 2
  • Uncontrollable third space effusion in clinical practice
  • Received or planned to undergo major surgery or intervention during the study period within the first 28 days of randomization
  • The researcher determined that there are other situations that are not suitable for participation in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
387 participants (actual)

Study arms

  • Experimental
    LM-302

    Patients will accept LM-302 monotherapy

    Drug: LM-302

  • Active comparator
    Physician's choice Apatinib or Irinotecan

    Patients will accept Apatinib or Irinotecan monotherapy

    Drug: Apatinib · Drug: Irinotecan

Interventions

  • DrugLM-302

    LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle

  • The subjects will receive Apatinib orally,qd

  • The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined defined as the time from date of randomization until death from any cause.

    Time frame: up to 42 months

  2. Progression Free Survival (PFS)

    PFS was defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on Investigator assessment

    Time frame: up to 42 months

Secondary outcomes

  1. Objective response rate (ORR)

    defined as the proportion of participants who achieve a best response of complete response (CR) or partial response (PR) using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by Investigator.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 42 months

  2. Duration of response (DoR)

    defined time from the initial response (CR or PR) until documented tumor progression or death from any cause and based on Investigator assessment.

    Time frame: Time from initial response (CR or PR) to date of documented disease progression or death (due to any cause) whichever occurs first, up to approximately 42 months

  3. Disease control rate (DCR)

    defined as the proportion of participants who achieved CR, PR, or stable disease (SD) for a minimum of 6 weeks during study treatment, based on Investigator assessment.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 42 months

  4. AE and SAE

    Adverse events will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0

    Time frame: From signing the ICF until 28 days after EOT or accept other anti-cancer therapy,up to 40 days after last study dose

  5. Evaluate the immunogenicity of LM-302

    Anti-drug antibody (ADA) will be detected, the titer of ADA will be evaluated using the validated assay.

    Time frame: up to 42 months

  6. Evaluation of pharmacokinetic characteristics of LM-302

    Peak Plasma Concentration (Cmax) will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  7. Evaluation of pharmacokinetic characteristics of LM-302

    Area under the plasma concentration versus time curve (AUC) will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  8. Evaluation of pharmacokinetic characteristics of LM-302

    Trough concentration will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  9. Evaluation of pharmacokinetic characteristics of total antibody

    Peak Plasma Concentration (Cmax) will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  10. Evaluation of pharmacokinetic characteristics of total antibody

    Area under the plasma concentration versus time curve (AUC) will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  11. Evaluation of pharmacokinetic characteristics of total antibody

    Trough concentration will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  12. Evaluation of pharmacokinetic characteristics of MMAE

    Peak Plasma Concentration (Cmax) will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  13. Evaluation of pharmacokinetic characteristics of MMAE

    Area under the plasma concentration versus time curve (AUC) will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

  14. Evaluation of pharmacokinetic characteristics of MMAE

    Trough concentration will be evaluated using PopPK model and simulation.

    Time frame: up to 42 months

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Apr 8, 2024
StartActual
Jun 24, 2024
Primary completionEst.
Nov 10, 2026
CompletionEst.
Dec 15, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06351020
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Jun 24, 2024
Primary completion
Nov 10, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Chunmei Bai
principal investigator · Peking Union Medical College Hospital
Jin Li
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tecotabart vedotin

Start the discussion